150 related articles for article (PubMed ID: 35361227)
1. Vascular endothelial growth factor-A level in human breast milk after intravitreal injection of ranibizumab: a case report.
Huang Y; Zhou R; Sun Z; Zheng Y; Lin B
Int Breastfeed J; 2022 Mar; 17(1):25. PubMed ID: 35361227
[TBL] [Abstract][Full Text] [Related]
2. Change of cytokines after intravitreal ranibizumab in patients with recurrent branch retinal vein occlusion and macular edema.
Noma H; Yasuda K; Shimura M
Eur J Ophthalmol; 2021 Jan; 31(1):204-210. PubMed ID: 31690095
[TBL] [Abstract][Full Text] [Related]
3. Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report.
Yoshimoto M; Takeda N; Yoshimoto T; Matsumoto S
J Med Case Rep; 2021 Jul; 15(1):403. PubMed ID: 34311786
[TBL] [Abstract][Full Text] [Related]
4. Ranibizumab and Aflibercept Levels in Breast Milk after Intravitreal Injection.
Juncal VR; Paracha Q; Bamakrid M; Francisconi CLM; Farah J; Kherani A; Muni RH
Ophthalmology; 2020 Feb; 127(2):278-280. PubMed ID: 31526521
[No Abstract] [Full Text] [Related]
5. Change in cardiac troponin T level after intravitreal anti-vascular endothelial growth factor treatment: Prospective pilot study.
Rebeiz AG; Mahfoud Z; Abdul Fattah M; Saad A; Safar A; Bashshur ZF
Eur J Ophthalmol; 2020 May; 30(3):563-569. PubMed ID: 30813779
[TBL] [Abstract][Full Text] [Related]
6. Retinal function determined by flicker ERGs before and soon after intravitreal injection of anti-VEGF agents.
Terauchi G; Shinoda K; Sakai H; Kawashima M; Matsumoto CS; Mizota A; Miyake Y
BMC Ophthalmol; 2019 Jun; 19(1):129. PubMed ID: 31208350
[TBL] [Abstract][Full Text] [Related]
7. Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications.
Blaha GR; Brooks NO; Mackel CE; Pani A; Stewart AP; Price LL; Barouch FC; Chang J; Marx JL
Retina; 2015 Mar; 35(3):577-81. PubMed ID: 25158942
[TBL] [Abstract][Full Text] [Related]
8. REVIEW OF OPHTHALMIC AND BREASTFEEDING MEDICINE EVIDENCE: Real and Theoretical Risks of Intravitreal Anti-Vascular Endothelial Growth Factor Administration in Lactating Women.
Dalal PJ; Patel AL; Carle M; Rajanala A; Gill MK
Retina; 2020 Nov; 40(11):2065-2069. PubMed ID: 32796446
[TBL] [Abstract][Full Text] [Related]
9. Healthcare resource use and costs of diabetic macular oedema for patients with antivascular endothelial growth factor versus a dexamethasone intravitreal implant in Korea: a population-based study.
Cho H; Choi KS; Lee JY; Lee D; Choi NK; Lee Y; Bae S
BMJ Open; 2019 Sep; 9(9):e030930. PubMed ID: 31542758
[TBL] [Abstract][Full Text] [Related]
10. Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion.
Hogg HJ; Di Simplicio S; Pearce MS
Eur J Ophthalmol; 2021 Mar; 31(2):548-555. PubMed ID: 32009462
[TBL] [Abstract][Full Text] [Related]
11. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
[TBL] [Abstract][Full Text] [Related]
12. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors for patients receiving intravitreal anti-vascular endothelial growth factor for the treatment of diabetic macular edema.
Carroll RM; Yu Y; VanderBeek BL
Eur J Ophthalmol; 2020 Jan; 30(1):72-80. PubMed ID: 30764665
[TBL] [Abstract][Full Text] [Related]
14. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
[TBL] [Abstract][Full Text] [Related]
15. Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
Borkar DS; Obeid A; Su DC; Storey PP; Gao X; Regillo CD; Kaiser RS; Garg SJ; Hsu J;
Am J Ophthalmol; 2018 Oct; 194():1-6. PubMed ID: 29981738
[TBL] [Abstract][Full Text] [Related]
16. The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema.
Guzel H; Bakbak B; Koylu MT; Gonul S; Ozturk B; Gedik S
Cutan Ocul Toxicol; 2017 Mar; 36(1):5-8. PubMed ID: 26911396
[TBL] [Abstract][Full Text] [Related]
17. Comparison of aflibercept and ranibizumab in diabetic macular edema associated with subretinal detachment.
Ozkaya A; Demir G; Kirmaci A
Eur J Ophthalmol; 2020 Mar; 30(2):363-369. PubMed ID: 30757913
[TBL] [Abstract][Full Text] [Related]
18. Real-life anti-vascular endothelial growth factor treatment for age-related macular degeneration and diabetic macular edema in an Italian tertiary referral hospital.
Battaglia Parodi M; Romano F; Arrigo A; Sacchi R; Scanzi G; Ferri C; Bandello F
Eur J Ophthalmol; 2020 Nov; 30(6):1461-1466. PubMed ID: 31617403
[TBL] [Abstract][Full Text] [Related]
19. Effects of intravitreal injection of ranibizumab on choroidal structure and blood flow in eyes with diabetic macular edema.
Okamoto M; Yamashita M; Ogata N
Graefes Arch Clin Exp Ophthalmol; 2018 May; 256(5):885-892. PubMed ID: 29492689
[TBL] [Abstract][Full Text] [Related]
20. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
